In the letter, Mason urges the CNMV to consider the benefits to all Grifols shareholders from improved disclosure around several key issues, including: The full text of the letter follows: Comisión ...

Abbott Laboratories, Novartis, and Grifols have reached a settlement in their long-running legal battle over a patent ...

Women are increasingly taking the lead at grand rounds, however, female grand lecturers are still markedly underrepresented ...

It is estimated that close to 1 million patients with ulcerative colitis live in the United States, 650.000 in the ... to be around $5.5 billion in 2017. Grifols has been awarded a $21m grant ...

MADRID (Reuters) - U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Initiative aims to identify plasma-based biomarkers for early detection Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...